Bio: Lympro is worth more than MSPrecise long term. While they are building an impressive diagnostics division, I don't think this division was ever meant to be something they would run long term. GC specifically stated they don't have the expertise in house for diagnostics like they do for therapeutics. It's a means to an end. If MANF, ESS, Eltoprazine, and Phenoguard are everything imagined then selling the diagnostics division is a very viable option to ensure development of those products listed above. I don't know the value of the diagnostics division today. I was just throwing out a number. It could be $.50 or $2 or $3. I don't know what someone would be willing to pay. It would likely be a cash plus royalty deal that would still bring revenue to the therapeutics division in perpetuity. It could also include shares for AMBS so they also have an asset on the balance sheet. It is an extremely viable option that is a win all around.